Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 949

Sort by

Sort Order Select

Journal Articles

Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma

Keri Toner, Lindsay A. Renfro, Hema Dave, Gloria Pezzella, Qinglin Pei, Lisa Giulino-Roth, Terzah Horton, Frank G. Keller, Kara M. Kelly, Sharon M. Castellino, Catherine M. Bollard

Blood Adv (2026) 10 (1): 183–191.

https://doi.org/10.1182/bloodadvances.2025016797

Published: 2026

Includes: Supplemental data

Journal Articles

Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel

Blood Adv (2026) 10 (1): 106–110.

https://doi.org/10.1182/bloodadvances.2025017012

Published: 2026

Journal Articles

Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group

Marion Aymard, Morgane Cheminant, Roch Houot, Anne Cuozzo, Elodie Gat, Catherine Thieblemont, Laure Ricard, Louise Roulin, Krimo Bouabdallah, Violaine Safar, Stéphanie Guidez, Amandine Fayard, Gabriel Brisou, Loic Ysebaert, Olivier Hermine, Benoît Tessoulin, Charles Herbaux, Steven Le Gouill, Clémentine Sarkozy

Blood Adv (2026) 10 (1): 75–82.

https://doi.org/10.1182/bloodadvances.2025017234

Published: 2026

Includes: Supplemental data

Journal Articles

Effect of obexelimab on the production of anti-RBC antibodies and cytokines in patients with warm autoimmune hemolytic anemia

Bruno Fattizzo, Anna Zaninoni, Giacinto Luca Pedone, Marta Bortolotti, Francesco Passamonti, Wilma Barcellini

Blood Adv (2026) 10 (1): 124–131.

https://doi.org/10.1182/bloodadvances.2025017722

Published: 2026

Journal Articles

Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium

Blood Adv (2026) 10 (1): 228–232.

https://doi.org/10.1182/bloodadvances.2025016968

Published: 2026

Journal Articles

Impact of Prior Bendamustine Exposure on Bispecific Antibody Outcomes in Relapsed/Refractory Follicular Lymphoma

Blood Adv bloodadvances.2025018546.

https://doi.org/10.1182/bloodadvances.2025018546

Published: 2026

Includes: Supplemental data

Journal Articles

Time to redefine HHV-8 MCD and KICS criteria?

Romain Stammler, Yannick Dieudonné, Anthony Vanjak, Eric Oksenhendler, Lionel Galicier, David Boutboul

Blood Adv (2025) 9 (24): 6590–6592.

https://doi.org/10.1182/bloodadvances.2025018106

Published: 2025

Journal Articles

A patient-derived CABIN1 mutation recapitulates features of idiopathic multicentric Castleman disease in a mouse model

Dorottya Laczko, Patricia Tsao, Ruth-Anne Pai, Joseph Zinski, Michael V. Gonzalez, Melanie D. Mumau, Tobias Raabe, Hiromi Muramatsu, Norbert Pardi, Taku Kambayashi, David C. Fajgenbaum

Blood Adv (2025) 9 (24): 6534–6537.

https://doi.org/10.1182/bloodadvances.2025016749

Published: 2025

Includes: Supplemental data

Journal Articles

Applying principles of vaccine development to oncomicrobial vaccines

Cody A. Despins, Nicholas J. P. Viegas, Robert A. Holt

Blood Adv (2025) 9 (24): 6469–6480.

https://doi.org/10.1182/bloodadvances.2024015610

Published: 2025

Journal Articles

Predictive markers for the efficacy of CAR T-cell therapy: the interplay between CAR T-cell fitness and systemic immunity

Kwai Han Yoo, Szymon Szymura, Zhenyuan Dong, Anmol Kandel, Soung-chul Cha, Larry W. Kwak

Blood Adv (2025) 9 (24): 6432–6442.

https://doi.org/10.1182/bloodadvances.2025017873

Published: 2025

Journal Articles

Systematic functional validation of IKAROS variants from patients and laboratory-generated mutations

Hye Sun Kuehn, Agustin Alejandro Gil Silva, Natchanun Klangkalya, Ana Esteve-Sole, Shubham Goel, Julie E Niemela, Jennifer L Stoddard, Hey Chong, Kelli W Williams, Winnie Ip, Mario Framil Seoane, Sathish K Loganathan, Ariharan Anantharachagan, Ana García-Soidán, Serena Beth Shaffren, Constance Bindernagel, Philip Mendez, Rahim Z Miller, Hassan Abolhassani, David P Hoytema van Konijnenburg, Ashley V Geerlinks, Diana Cabanillas, Evelien Zonneveld-Huijssoon, Abraham Rutgers, Stuart G. Tangye, Cindy S Ma, Alice Grey, Patrick O'Young, Juan Carlos Aldave Becerra, Jonathan J Lyons, Andrew White, Michael Claiborne, Ali Doroudchi, Brian D Modena, Joshua D. Milner, Xavier Solanich, João Farela Neves, Craig Platt, Lennart Hammarström, John Routes, James Verbsky, Manish Butte, Harry Lesmana, William JH Griffiths, Dinakantha S Kumararatne, Fabian Hauck, Luis M Allende, Carlos Rodríguez-Gallego, Reem Elfeky, Tamar Sarah Rubin, Kaan Boztug, Thomas A. Fleisher, Sergio D Rosenzweig

Blood Adv bloodadvances.2025017243.

https://doi.org/10.1182/bloodadvances.2025017243

Published: 2025

Includes: Supplemental data

Journal Articles

Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe

Blood Adv (2025) 9 (24): 6380–6393.

https://doi.org/10.1182/bloodadvances.2025017081

Published: 2025

Includes: Supplemental data

Journal Articles

Dual anti-CD19/22 and anti-BCMA CAR T-cell therapy in a patient with multiple myeloma and secondary B-ALL

Malte Roerden, Luca Hensen, Britta Besemer, Friederike Schwartz, Kristina Reuss, Alisha Weiss-Haug, Lennart Harland, Franziska Ginsberg, Christoph Faul, Wolfgang Bethge, Claudia Lengerke

Blood Adv (2025) 9 (24): 6340–6344.

https://doi.org/10.1182/bloodadvances.2025017770

Published: 2025

Journal Articles

CAR T cells targeting C-C motif chemokine receptor 4 (CCR4) selectively deplete human Tregs ex vivo and in vivo

Caitlin M Tilsed, Karen P Fong, Xinyi Shi, Tatiana Akimova, Liqing Wang, Estela Noguera-Ortega, Ryan Krouse, Andres Bermudez, Sunil Singhal, Regina M. Young, Evgeniy Eruslanov, Keisuke Watanabe, Wayne W. Hancock, Carl H. June, Steven Albelda

Blood Adv bloodadvances.2025017573.

https://doi.org/10.1182/bloodadvances.2025017573

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction

Jeremy D. Rubinstein, Giang Pham, Anusha Sridharan, Ruby Khoury, YunZu M. Wang, Zahra Hudda, Jamie Wilhelm, Daniel A. Lichtenstein, Daria Heyenbruch, Jose A. Cancelas, Stella M. Davies, Carolyn Lutzko, Michael S. Grimley

Blood Adv (2025) 9 (24): 6305–6313.

https://doi.org/10.1182/bloodadvances.2025017097

Published: 2025

Includes: Supplemental data

Journal Articles

Elevated Lactate in AML Bone Marrow Contributes to Macrophage Polarization via GPR81 Signaling

Celia A Soto, Maggie L Lesch, Jennifer L Becker, Azmeer Sharipol, Amal Khan, Xenia L Schafer, Zhewen Li, Amanda R. Streeter, Michael W Becker, Joshua C Munger, Benjamin J Frisch

Blood Adv bloodadvances.2025016400.

https://doi.org/10.1182/bloodadvances.2025016400

Published: 2025

Includes: Supplemental data

Journal Articles

Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosis

Blood Adv bloodadvances.2025017643.

https://doi.org/10.1182/bloodadvances.2025017643

Published: 2025

Includes: Supplemental data

Journal Articles

Harmonized immune recovery monitoring after HCT: evidence and practical guidance from the Westhafen Intercontinental Group

Blood Adv (2025) 9 (23): 6141–6157.

https://doi.org/10.1182/bloodadvances.2025016915

Published: 2025

Journal Articles

mTOR activity and metabolic reprogramming of CD8 + T cells is impaired under hypoxia and within the multiple myeloma bone marrow

Taylor Fulton-Ward, Nancy Gudgeon, Isaac Thirlwell, Emma L. Bishop, Bryan Marzullo, Hannah Giles, Graham McIlroy, Paul Ferguson, Bhuvan Kishore, Kate Rogers, Nuri Alfasi, Timothy Wong, Satnam Aytain, Daniel A. Tennant, Guy Pratt, Sarah Dimeloe

Blood Adv (2025) 9 (23): 6175–6188.

https://doi.org/10.1182/bloodadvances.2025016439

Published: 2025

Includes: Supplemental data

Journal Articles

FLT3-directed BiTE Molecules versus CAR T Cells in AML: Co-stimulatory Signals Mitigate T-Cell Exhaustion

Blood Adv bloodadvances.2025018168.

https://doi.org/10.1182/bloodadvances.2025018168

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma

Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel

Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group

Effect of obexelimab on the production of anti-RBC antibodies and cytokines in patients with warm autoimmune hemolytic anemia

Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium

Impact of Prior Bendamustine Exposure on Bispecific Antibody Outcomes in Relapsed/Refractory Follicular Lymphoma

Time to redefine HHV-8 MCD and KICS criteria?

A patient-derived CABIN1 mutation recapitulates features of idiopathic multicentric Castleman disease in a mouse model

Applying principles of vaccine development to oncomicrobial vaccines

Predictive markers for the efficacy of CAR T-cell therapy: the interplay between CAR T-cell fitness and systemic immunity

Systematic functional validation of IKAROS variants from patients and laboratory-generated mutations

Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe

Dual anti-CD19/22 and anti-BCMA CAR T-cell therapy in a patient with multiple myeloma and secondary B-ALL

CAR T cells targeting C-C motif chemokine receptor 4 (CCR4) selectively deplete human Tregs ex vivo and in vivo

Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction

Elevated Lactate in AML Bone Marrow Contributes to Macrophage Polarization via GPR81 Signaling

Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosis

Harmonized immune recovery monitoring after HCT: evidence and practical guidance from the Westhafen Intercontinental Group

mTOR activity and metabolic reprogramming of CD8 + T cells is impaired under hypoxia and within the multiple myeloma bone marrow

FLT3-directed BiTE Molecules versus CAR T Cells in AML: Co-stimulatory Signals Mitigate T-Cell Exhaustion

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only